12 completed. 12 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 12 |
| Phase 1 | 1 | Completed 1 |
Follow Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Advanced Malignant Solid Neoplasm trials Research Report on Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Infigratinib - Advanced Malignant Solid Neoplasm, Cholangiocarcinoma | Phase 2 | Completed | Sameek Roychowdhury | 17 | 2020-01-16 | 2026-02-24 |
| BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab - Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 51 | 2019-08-19 | 2025-12-03 |
| AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Adavosertib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2019-01-16 | 2023-10-17 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2017-10-30 | 2025-02-05 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) FGFR Inhibitor AZD4547 - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2016-05-31 | 2021-06-29 |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) Nivolumab - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2016-05-31 | 2021-04-06 |
| MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations Adavosertib, Carboplatin, Everolimus - Advanced Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 208 | 2014-01-07 | 2023-09-29 |
Lymphoma, Non-Hodgkin (6) · Neuroblastoma (6) · Central Nervous System Neoplasms (5) · Ependymoma (5) · Glioma (5) · Hepatoblastoma (5) · Histiocytosis, Langerhans-Cell (5) · Neuroectodermal Tumors, Primitive, Peripheral (5) · Osteosarcoma (5) · Rhabdoid Tumor (5) · Rhabdomyosarcoma (5) · Sarcoma (5) · Wilms Tumor (5) · Medulloblastoma (4) · Sarcoma, Ewing (4)
Neoplasms (10) · Neoplasms by Histologic Type (9) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms by Site (8) · Neoplasms, Glandular and Epithelial (7) · Lymphoma (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (6) · Neuroectodermal Tumors (6) · Neuroectodermal Tumors, Primitive (6)
Nivolumab (2) · adavosertib (2) · AZD 6244 (1) · AZD4547 (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Everolimus (1) · Ipilimumab (1) · LY3023414 (1) · Magnetic Resonance Spectroscopy (1) · Phantoms, Imaging (1) · Radiosurgery (1) · Specimen Handling (1) · Temozolomide (1) · Vemurafenib (1)
National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (1) · Sameek Roychowdhury (1)
United States (12) · Puerto Rico (6)
A P Chen (1) · AeRang Kim (1) · Carl E Allen (1) · Joe Chang (1) · Julia Glade-Bender (1) · Nilofer S Azad (1) · Rajen Mody (1) · Sameek Roychowdhury, M.D. (1) · Siqing Fu (1) · Susan N Chi (1) · Theodore W Laetsch (1) · Young Kwang Chae (1)
PMID 31401903, PMID 26602013, PMID 31765263, PMID 32463741, PMID 35363510, PMID 36469840, PMID 38815151, PMID 38873934, PMID 39298716, PMID 39384194
U10CA180886 (6), U10CA180820 (2), U24CA196172 (2), UM1CA186688 (1), ZIABC011078 (1)